JP2015527343A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015527343A5 JP2015527343A5 JP2015525636A JP2015525636A JP2015527343A5 JP 2015527343 A5 JP2015527343 A5 JP 2015527343A5 JP 2015525636 A JP2015525636 A JP 2015525636A JP 2015525636 A JP2015525636 A JP 2015525636A JP 2015527343 A5 JP2015527343 A5 JP 2015527343A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- carrier
- cell
- polypeptide
- phage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679306P | 2012-08-03 | 2012-08-03 | |
| US61/679,306 | 2012-08-03 | ||
| PCT/US2013/053493 WO2014022811A1 (en) | 2012-08-03 | 2013-08-02 | Isolating traffic-enhancing mutants of drug delivery protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019132760A Division JP2020002138A (ja) | 2012-08-03 | 2019-07-18 | 薬物送達タンパク質の輸送向上変異体の単離 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015527343A JP2015527343A (ja) | 2015-09-17 |
| JP2015527343A5 true JP2015527343A5 (cg-RX-API-DMAC7.html) | 2016-09-15 |
| JP6618360B2 JP6618360B2 (ja) | 2019-12-11 |
Family
ID=50028570
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525636A Expired - Fee Related JP6618360B2 (ja) | 2012-08-03 | 2013-08-02 | 薬物送達タンパク質の輸送向上変異体の単離 |
| JP2019132760A Pending JP2020002138A (ja) | 2012-08-03 | 2019-07-18 | 薬物送達タンパク質の輸送向上変異体の単離 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019132760A Pending JP2020002138A (ja) | 2012-08-03 | 2019-07-18 | 薬物送達タンパク質の輸送向上変異体の単離 |
Country Status (18)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9078927B2 (en) | 2007-07-06 | 2015-07-14 | Cedars-Sinai Medical Center | Self-assembling complex for targeting chemical agents to cells |
| WO2010085665A2 (en) | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
| EP2880160B1 (en) * | 2012-08-03 | 2018-09-19 | Cedars-Sinai Medical Center | Isolating traffic-enhancing mutants of drug delivery protein |
| US9757386B2 (en) | 2013-05-08 | 2017-09-12 | Cedars-Sinai Medical Center | Targeting corroles for tumor toxicity and MRI |
| CN106413738B (zh) | 2014-01-17 | 2020-12-29 | 席德-西奈医疗中心 | 受体靶向构造物和其使用 |
| RU2692104C2 (ru) | 2014-04-04 | 2019-06-21 | Сидарс-Синай Медикал Сентр | Адресное воздействие на устойчивый к трастузумабу her2+ рак молочной железы посредством her3-нацеленных наночастиц |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5439829A (en) | 1991-01-30 | 1995-08-08 | Eli Lilly And Company | Immobilization of biologically active molecules by changing the Oxidation state of a chelated transition metal ion |
| US6287792B1 (en) | 1991-06-17 | 2001-09-11 | The Regents Of The University Of California | Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology |
| GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
| US5547945A (en) | 1993-07-15 | 1996-08-20 | Jcr Pharmaceuticals Co., Ltd. | Remitting agent for nephrotic syndrome and hepatopathy symptoms |
| US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US6465253B1 (en) * | 1994-09-08 | 2002-10-15 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| US6066322A (en) | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
| CZ162398A3 (cs) * | 1995-11-28 | 1998-10-14 | Gen Vec, Inc. | Vektory a způsoby pro genový přenos do buněk |
| JP4515542B2 (ja) | 1997-02-10 | 2010-08-04 | ジェネンテック， インコーポレイテッド | ヒレグリン変異体 |
| GB9709421D0 (en) | 1997-05-10 | 1997-07-02 | Zeneca Ltd | Chemical compounds |
| NZ509271A (en) | 1998-08-18 | 2003-10-31 | Univ California | Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs |
| US6333396B1 (en) | 1998-10-20 | 2001-12-25 | Enzon, Inc. | Method for targeted delivery of nucleic acids |
| CA2391534A1 (en) | 1999-11-15 | 2001-05-25 | Drug Innovation & Design, Inc. | Selective cellular targeting: multifunctional delivery vehicles |
| WO2001096871A2 (en) | 2000-06-16 | 2001-12-20 | Martek Biosciences Corporation | Recombinant phycobiliprotein and phycobiliprotein linker fusion proteins and uses therefore |
| IT1318704B1 (it) * | 2000-09-22 | 2003-08-27 | Consorzio Interuniversitario P | Vettori chimerici e loro uso per il trasferimento di geni eterologhi. |
| AU2002240201A1 (en) | 2001-02-02 | 2002-08-19 | Yale University | Peptides for facilitating composite receptor expression and translocation of macromolecules |
| EP1266963A1 (en) * | 2001-06-15 | 2002-12-18 | Crucell Holland B.V. | Chimaeric phages |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| US7329638B2 (en) | 2003-04-30 | 2008-02-12 | The Regents Of The University Of Michigan | Drug delivery compositions |
| US7205387B2 (en) | 2003-08-28 | 2007-04-17 | Agency For Science, Technology And Research | Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist |
| WO2005117928A1 (en) | 2004-05-30 | 2005-12-15 | Cemines, Inc. | Compositions and methods for the treatment of skin cancer |
| US8057821B2 (en) | 2004-11-03 | 2011-11-15 | Egen, Inc. | Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof |
| WO2007137117A2 (en) | 2006-05-17 | 2007-11-29 | Massachusetts Institute Of Technology | Aptamer-directed drug delivery |
| JP4479755B2 (ja) | 2007-07-03 | 2010-06-09 | ソニー株式会社 | 有機エレクトロルミネッセンス素子、及び、有機エレクトロルミネッセンス表示装置 |
| US9078927B2 (en) * | 2007-07-06 | 2015-07-14 | Cedars-Sinai Medical Center | Self-assembling complex for targeting chemical agents to cells |
| AU2008331906B2 (en) * | 2007-11-28 | 2014-03-06 | The Trustees Of The University Of Pennsylvania | Simian E adenovirus SAdV-39 |
| WO2010085665A2 (en) | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
| EP2764011B1 (en) | 2011-10-05 | 2021-04-07 | GenVec, Inc. | Adenoviral vector-based respiratory syncytial virus (rsv) vaccine |
| EP2880160B1 (en) | 2012-08-03 | 2018-09-19 | Cedars-Sinai Medical Center | Isolating traffic-enhancing mutants of drug delivery protein |
| US9757386B2 (en) | 2013-05-08 | 2017-09-12 | Cedars-Sinai Medical Center | Targeting corroles for tumor toxicity and MRI |
| CN106413738B (zh) * | 2014-01-17 | 2020-12-29 | 席德-西奈医疗中心 | 受体靶向构造物和其使用 |
| RU2692104C2 (ru) * | 2014-04-04 | 2019-06-21 | Сидарс-Синай Медикал Сентр | Адресное воздействие на устойчивый к трастузумабу her2+ рак молочной железы посредством her3-нацеленных наночастиц |
| EA201892797A1 (ru) * | 2016-05-27 | 2019-06-28 | Седарс-Синаи Медикал Сентер | Наночастицы для доставки лекарственных средств и способы лечения лекарственно-резистентного рака |
-
2013
- 2013-08-02 EP EP13826083.1A patent/EP2880160B1/en not_active Not-in-force
- 2013-08-02 KR KR1020157005438A patent/KR102115630B1/ko not_active Expired - Fee Related
- 2013-08-02 BR BR112015002004A patent/BR112015002004A2/pt not_active Application Discontinuation
- 2013-08-02 PL PL13826083T patent/PL2880160T3/pl unknown
- 2013-08-02 ES ES13826083T patent/ES2703052T3/es active Active
- 2013-08-02 JP JP2015525636A patent/JP6618360B2/ja not_active Expired - Fee Related
- 2013-08-02 WO PCT/US2013/053493 patent/WO2014022811A1/en not_active Ceased
- 2013-08-02 DK DK13826083.1T patent/DK2880160T3/en active
- 2013-08-02 AU AU2013296218A patent/AU2013296218B2/en not_active Ceased
- 2013-08-02 MX MX2015001366A patent/MX366347B/es active IP Right Grant
- 2013-08-02 PT PT13826083T patent/PT2880160T/pt unknown
- 2013-08-02 US US14/419,233 patent/US10036009B2/en active Active
- 2013-08-02 CN CN201380041215.1A patent/CN104619839A/zh active Pending
- 2013-08-02 CA CA2881582A patent/CA2881582A1/en not_active Abandoned
- 2013-08-02 RU RU2015105052A patent/RU2015105052A/ru not_active Application Discontinuation
-
2015
- 2015-01-28 IL IL236955A patent/IL236955A0/en unknown
- 2015-02-02 ZA ZA2015/00739A patent/ZA201500739B/en unknown
- 2015-02-13 IN IN1196DEN2015 patent/IN2015DN01196A/en unknown
-
2018
- 2018-06-25 US US16/017,866 patent/US10752893B2/en active Active
-
2019
- 2019-07-04 AU AU2019204815A patent/AU2019204815A1/en not_active Abandoned
- 2019-07-18 JP JP2019132760A patent/JP2020002138A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015527343A5 (cg-RX-API-DMAC7.html) | ||
| Wang et al. | Efficient genome editing in Fusarium oxysporum based on CRISPR/Cas9 ribonucleoprotein complexes | |
| US11946040B2 (en) | Adenine DNA base editor variants with reduced off-target RNA editing | |
| EP4021945A2 (en) | Combinatorial adenine and cytosine dna base editors | |
| Yuan et al. | Advances of mRNA vaccine in tumor: a maze of opportunities and challenges | |
| Bourgeois et al. | A highly characterized synthetic landing pad system for precise multicopy gene integration in yeast | |
| David et al. | A perspective on synthetic biology in drug discovery and development—current impact and future opportunities | |
| IL263375A (en) | Methods and preparations for integrating exogenous sequence into the genome of plants | |
| JP2018510628A5 (cg-RX-API-DMAC7.html) | ||
| RU2015105052A (ru) | Выделение мутантов белка доставки лекарственного средства, усиливающих направленную миграцию | |
| NZ723978A (en) | Genes involved in noscapine production | |
| JP2016537028A5 (cg-RX-API-DMAC7.html) | ||
| Taton et al. | Heterologous expression of cryptomaldamide in a cyanobacterial host | |
| JP2013530689A5 (cg-RX-API-DMAC7.html) | ||
| Zhu et al. | Using defined finger–finger interfaces as units of assembly for constructing zinc-finger nucleases | |
| Yuan et al. | Manipulation of the global regulator mcrA upregulates secondary metabolite production in Aspergillus wentii using CRISPR-Cas9 with in vitro assembled ribonucleoproteins | |
| JP2014527801A5 (cg-RX-API-DMAC7.html) | ||
| Loya et al. | Yeast Nab3 protein contains a self-assembly domain found in human heterogeneous nuclear ribonucleoprotein-C (hnRNP-C) that is necessary for transcription termination | |
| AR026571A1 (es) | Genes del musgo de la physcomitrella patens que codifican proteinas que participan en la sintesis de los acidos grasos poliinsaturados y lipidos | |
| Zhou et al. | Applications of CRISPR technology in cellular immunotherapy | |
| JP2015524788A5 (cg-RX-API-DMAC7.html) | ||
| JP2013530965A5 (cg-RX-API-DMAC7.html) | ||
| Gehrke et al. | Current non-viral-based strategies to manufacture CAR-T cells | |
| CA2475276A1 (en) | Zinc finger libraries | |
| Kacherovsky et al. | Multiplexed gene transfer to a human T‐cell line by combining Sleeping Beauty transposon system with methotrexate selection |